Home/Pipeline/HX044

HX044

Undisclosed

Phase 1IND approved by NMPA

Key Facts

Indication

Undisclosed

Phase

Phase 1

Status

IND approved by NMPA

Company

HanX Biopharmaceuticals

About HanX Biopharmaceuticals

Clinical-stage Chinese biotech developing novel antibody therapies for oncology and immunology with multiple IND approvals.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Technosphere Platform (New Formulations)	MannKind	Discovery/Preclinical	Active R&D
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active